AlQahtani Reham Dakam, Al Owaifeer Adi Mohammed, AlShahwan Sami, AlZaben Khawlah, AlMansour Raghad
King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Ophthalmology Unit, Department of Surgery, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
Clin Ophthalmol. 2023 Mar 9;17:797-806. doi: 10.2147/OPTH.S385864. eCollection 2023.
To report the outcomes of medical and surgical management in patients diagnosed with aqueous misdirection syndrome (AMS).
A retrospective chart review of all cases diagnosed with AMS at a single tertiary care eye center during the period from 2014 to 2021. Outcome measures were anatomical success (deepening of the anterior chamber (AC)), functional success (improvement in visual acuity), and treatment success (control of intraocular pressure (IOP)).
A total of 26 eyes with AMS from 24 patients were included. The patients were followed for a mean duration of 24 ± 18 months. Although some patients initially responded to medical and laser therapy, all but one (3.8%) eventually required surgery during the first 3 months after presentation. The mean duration from presentation until surgery was 45.9 ± 45.8 days (range: 2-119 days). The majority of cases (69.2%) were managed by pars plana vitrectomy. At the last follow-up visit, anatomical success was achieved in 20 (76%) eyes, 15 (57%) eyes had a final visual acuity that was either similar to or better than baseline, and successful control of IOP was achieved in 17 (65%) eyes. Univariate analysis revealed that a history of trabeculectomy as a cause of AMS was a risk factor for treatment failure (OR, 7.8; 95% CI, 1.16-52.35; P, 0.02).
Our findings indicate that medical and laser management of AMS provide temporary control, and almost all patients eventually require surgery within the first 3 months. A history of trabeculectomy was found to be a risk factor for treatment failure.
报告诊断为房水错流综合征(AMS)患者的药物和手术治疗结果。
对2014年至2021年期间在单一三级眼科护理中心诊断为AMS的所有病例进行回顾性病历审查。结果指标包括解剖学成功(前房加深)、功能成功(视力提高)和治疗成功(眼压控制)。
纳入了24例患者的26只患有AMS的眼睛。患者平均随访时间为24±18个月。尽管一些患者最初对药物和激光治疗有反应,但除1例(3.8%)外,所有患者在就诊后的前3个月内最终都需要手术。从就诊到手术的平均时间为45.9±45.8天(范围:2 - 119天)。大多数病例(69.2%)采用了玻璃体切除术。在最后一次随访时,20只(76%)眼睛实现了解剖学成功,15只(57%)眼睛的最终视力与基线相似或更好,17只(65%)眼睛成功控制了眼压。单因素分析显示,小梁切除术病史作为AMS的病因是治疗失败的危险因素(OR,7.8;95%CI,1.16 - 52.35;P,0.02)。
我们的研究结果表明,AMS的药物和激光治疗可提供临时控制,几乎所有患者最终在3个月内都需要手术。发现小梁切除术病史是治疗失败的危险因素。